Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-07
2005-06-07
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S580000
Reexamination Certificate
active
06903090
ABSTRACT:
Disclosed are compounds of Formula (I):wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.
REFERENCES:
patent: 3525750 (1970-08-01), Renner
patent: 3553232 (1971-01-01), Hester, Jr.
patent: 3622673 (1971-11-01), Hester, Jr.
patent: 3652588 (1972-03-01), Hester, Jr.
patent: 3676558 (1972-07-01), Hester, Jr.
patent: 3776922 (1973-12-01), Epstein et al.
patent: 3839357 (1974-10-01), Hester, Jr.
patent: 6221866 (2001-04-01), Brendel et al.
patent: 6503899 (2003-01-01), Fu
patent: 2002/0022616 (2002-02-01), Fu
patent: 636232 (1993-04-01), None
patent: 1062840 (1967-03-01), None
patent: 3315467 (1983-11-01), None
patent: 0028381 (1981-05-01), None
patent: 0377238 (1990-07-01), None
patent: 0466548 (1991-06-01), None
patent: 6699 (1969-02-01), None
patent: 1180615 (1970-02-01), None
patent: 2120662 (1983-12-01), None
patent: 63-163347 (1988-07-01), None
patent: WO-00/64899 (2000-11-01), None
patent: WO-00/77001 (2000-12-01), None
patent: WO-00/77002 (2000-12-01), None
patent: WO-00/77010 (2000-12-01), None
patent: WO-01/00573 (2001-01-01), None
patent: WO-01/05793 (2001-01-01), None
Abstract of NL 6515701 (1966).
Abstract of Harley-Mason et al. (Journal of the Chemical Society, Abstracts (1955), 374-6).
Artemenko, G. N., “Pharmacological acitivity spectra of some azepino- and benzoxepinoindole derivatives”,CAPLUS Abstract,(1972),1 pg.
Baxter, G., “5-HT2 receptor subtypes: a family re-united?”,Trends in Pharmacological Reviews, 16,(1995),pp. 105-110.
Bos, M., “Novel Antagonists of 5HT2C Receptors. Synthesis and Biological Evaluation of Substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved Therapeutics for Obsessive Compulsive Disorder”,Journal of Medicinal Chemistry, 40(17), (Aug. 15, 1997),pp. 2762-2769.
Bromidge, S. M., “Novel and Selective 5-HT2C/2B Receptor Antagonists as Potential Anxiolytic Agents: Synthesis, Quantitative Structure-Activity Relationships, and Molecular Modeling of Substituted 1-(3-Pyridylcarbamoyl)indolines”,Journal of Medicinal Chemistry, 49(10), (May 7, 1998),pp. 1598-1612.
Dekeyne, A. , “Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis”,Neuropharmacology, 38(2), (Mar. 1999),pp. 415-423.
Glennon, R. A., “Serotonin Receptors: Clinical Implications”,Neuroscience&Behavioral Reviews, 14(1), (1990),pp. 35-47.
Hoyer, D. , “VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin)”,Pharmacological Reviews, 46(2), (Jun. 1994),pp. 157-203.
Jenck, F. , “The role of 5-HT2C receptors in affective disorders”,Exp. Opin. Invest. Drugs, 7(10), (1998),pp. 1587-1599.
Kennett, G A., et al., “5-HT drugs and eating disorders”,IDrugs, 1(4), (1998),pp. 456-470.
Martin, J. R., “5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential”,The Journal of Pharmacology and Experimental Therapeutics, 286(2), (1998),pp. 913-924.
Zagorevskii, V. A., et al., “Synthesis and reactions of 2,2-dimethyl-4-chloromethyl-1,2,34-tetrahydro-gamma-carboline”,Chemical Abstracts Service, Accession No. 94: 121373,(1980), 1387-1390.
Barkov, N. K., et al., “Pharmacological properties of carazedine”,Eksp. Klin. Farmakol.,57(2), CAPLUS Abstract, (1994) 1 page.
Boullin, D. J.,Serotonin in Mental Abnormalities,John Wiley & Sons, Ltd., (1978), pp. 1-316.
Diker, K., et al., “Practical synthesis of hexahydroazepino[4,5 -b]- and hexahydroazocino[4,5-b]indoles”,Tetrahedron Lett.,36(20), CAPLUS Abstract, (1995), 1 page.
Gershon, M. D., et al., “5-Hydroxytryptamine and enteric neurons”,The Peripheral Actions of 5-Hydroxytryptamine,Chapter 11, Oxford University Press, (1989), pp. 247-273.
Hester, J. B., et al., “Azepinoindoles. I. Hexahydroazepino(4,5-b) indoles”,J. Med. Chem,11, No. 1, (1968), pp. 101-106.
Kalaus, G., et al., “Synthesis of vinca alkaloids and related compounds. Part LXXXIX. Some unexpected reactions of compounds containing the D-seco-aspidospermane ring system”,Heterocytes,47(1), CAPLUS abstract, (1998), 2 pages.
Kelley, J. M., et al., “Comparison of common interatomic distances in serotonin and some hallucinogenic drugs”,Pharmacology,CAPLUS abtract, 10(1), (1973), 1 page.
Kucherova, N. F., et al., “3,9-Dimethyl-1,2,3,4,5,5a,6, 10b-octahydroazepino [4,5-b]indole”,Izobret., Prom. Obraztsy, Tovarnye Znaki,CAPLUS abstract, 45(13), (1968), 1 page.
Mash, D. C., et al., “Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin”,Life Sci.,57(3), CAPLUS Abstract, (1995) 1 page.
Robichaud, A. J., et al., “Recent Advances in Selective Serotonin Receptor Modulation”,Annual Reports in Medicinal Chemistry,vol. 36, (2000), pp. 11-20.
Saxena, P. R., et al., “Cardiovascular Effects of Serotonin Agonists and Antagonists”,Journal of Cardiovascular Pharmacology,15(Suppl. 7), (1990), pp. S17-S34.
Saxena, P. R., “Serotonin Receptors: Subtypes, Functional Responses and Therapeutic Relevance”,Pharmac. Ther.,66, (1995), pp. 339-368.
Sharkova, N. M., et al., “Indole Derivatives. XXVIV. Synthesis of some new polycondensed indole systems”, Khim Geterotsikl. Soedin., vol. 1, CAPLUS Abstract, (1969), 1 page.
Sweetnam, P. M., et al., “Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity”,Psychopharmacology,vol. 118, (1995), pp. 369-376.
Acker Brad A.
Ennis Michael D.
Fisher Jed F.
Frank Kristine E.
Fu Jian-min
Kifle Bruck
Pfizer
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Substituted azepino[4,5b]indole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted azepino[4,5b]indole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted azepino[4,5b]indole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3510692